DFDA

Calcium Channel Blockers (e.g., Verapamil, Diltiazem)

Treatment for Hypertrophic Cardiomyopathy

Typical Dosage: Verapamil 120-480mg daily

Effectiveness
65%
Safety Score
70%
Clinical Trials
400
Participants
40K

Comparative Safety Scale(Higher is safer)

Cyanide☠ī¸
Meth💀
CigarettesđŸšŦ
Chemoâ˜ĸī¸
AlcoholđŸē
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
Verapamil 120-480mg daily
Time to Effect
Hours to days
Treatment Duration
Lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100
Monitoring:$400
Side Effect Mgmt:$100
Total Annual:$600
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
QALYs Gained
5
Outcome-Based Costs
Cost per Responder
$923
Prescription Access Economics
Risk Assessment
Requires Monitoring
Yes
Needs lab work/checkups
Calcium Channel Blockers (e.g., Verapamil, Diltiazem) Outcomes

for Hypertrophic Cardiomyopathy

Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+65%
Common Side Effects
Constipation (Verapamil)
+15%
Headache
+8%
Dizziness
+7%
Bradycardia
+5%
Hypotension
+5%

Sources:

nih.gov
dntb.gov.ua
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov